U.S. FDA approves Stemline Therapeutics' rare blood disease treatment
The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc's Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.
No comments:
Post a Comment